Drug Trial Radar · NCT06425302
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
95
Actual
Start
Aug 30, 2024
Primary completion
Jun 19, 2026
Study completion Nov 27, 2028
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
Conditions
- Lymphoma, Follicular
Interventions
GolcadomideDrug
Specified dose on specified days
RituximabDrug
Specified dose on specified days
CyclophosphamideDrug
Specified dose on specified days
DoxorubicinDrug
Specified dose on specified days
VincristineDrug
Specified dose on specified days
PrednisoneDrug
Specified dose on specified days
BendamustineDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who achieve complete metabolic response (CMR) as assessed by Lugano criteria 2014Time frame: Up to approximately 12 months from participant randomization
Locations
56 sites in 13 countries. Site status is shown where the registry gives one.
Local Institution - 0152
Birmingham, Alabama
Local Institution - 0055
Anchorage, Alaska
Local Institution - 0180
Phoenix, Arizona
Local Institution - 0190
Tucson, Arizona
Local Institution - 0035
San Francisco, California
Local Institution - 0022
Washington D.C., District of Columbia
Local Institution - 0209
Fort Myers, Florida
Local Institution - 0005
Jacksonville, Florida
Local Institution - 0210
St. Petersburg, Florida
Local Institution - 0026
Tampa, Florida
Local Institution - 0208
West Palm Beach, Florida
Local Institution - 0019
Westwood, Kansas
Local Institution - 0031
Rochester, Minnesota
Local Institution - 0111
Henderson, Nevada
Local Institution - 0183
Hackensack, New Jersey
Local Institution - 0052
Salt Lake City, Utah
Local Institution - 0201
Norfolk, Virginia
Local Institution - 0202
Seattle, Washington
Local Institution - 0046
Liverpool, New South Wales, Australia
Local Institution - 0070
South Brisbane, Queensland, Australia
Local Institution - 0181
Traralgon, Victoria, Australia
Local Institution - 0060
Rio de Janeiro, Brazil
Local Institution - 0058
São Paulo, Brazil
Local Institution - 0056
São Paulo, Brazil
Local Institution - 0061
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0064
Toronto, Ontario, Canada
Local Institution - 0205
Chicoutimi, Quebec, Canada
Local Institution - 0049
Santiago, Santiago Metropolitan, Chile
Local Institution - 0050
Santiago, Santiago Metropolitan, Chile
Local Institution - 0118
Paris, France
Local Institution - 0101
Saint-Cloud, Hauts-de-Seine, France
Local Institution - 0103
Lille, Nord, France
Local Institution - 0121
Poitiers, Vienne, France
Local Institution - 0189
Dresden, Germany
Local Institution - 0197
Regensburg, Bavaria, Germany
Local Institution - 0188
Chemnitz, Saxony, Germany
Local Institution - 0076
Bologna, Italy
Local Institution - 0075
Naples, Italy
Local Institution - 0198
Rome, Lazio, Italy
Local Institution - 0179
Rozzano, Milano, Italy
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.